Vida Ventures

Type

Venture Capital

Status

Active

Location

Boston, United States

Total investments

53

Average round size

98M

Portfolio companies

35

Rounds per year

7.57

Lead investments

12

Follow on index

0.34

Exits

11

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareWellnessMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsChemicalBiopharma

Summary

In 2017 was created Vida Ventures, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Boston.

This organization was formed by Arjun Goyal, Len Potter, Stefan Vitorovic. Besides them, we counted 4 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Vida Ventures, startups are often financed by SV Health Investors, Skyline Ventures, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Nextech Invest, OrbiMed, The Column Group. In the next rounds fund is usually obtained by Perceptive Advisors, Nextech Invest, venBio Select Advisor.

Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, Pionyr Immunotherapeutics, Kronos Bio. The fund has no exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical Device. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year. The common things for fund are deals in the range of more than 100 millions dollars. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2018. This Vida Ventures works on 4 percentage points more the average amount of lead investments comparing to the other organizations.

Show more

Investor highlights

Industry focus
Biotech/Life Sciences
Stage focus
Generalist

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 825000000
Fund raised date
2021-06-24

Analytics

Total investments
53
Lead investments
12
Exits
11
Rounds per year
7.57
Follow on index
0.34
Investments by industry
  • Biotechnology (46)
  • Health Care (24)
  • Therapeutics (20)
  • Pharmaceutical (15)
  • Medical (14)
  • Show 17 more
Investments by region
  • United States (49)
  • China (1)
  • Netherlands (1)
  • France (1)
  • India (1)
Peak activity year
2020
Number of Unicorns
2
Number of Decacorns
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
6
Avg. valuation at time of investment
113M
Group Appearance index
0.98
Avg. company exit year
9
Avg. multiplicator
3.26
Strategy success index
0.60

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Aktis Oncology 25 Aug 2022 Biotechnology, Life Science Early Stage Venture 84M United States, Massachusetts, Boston
InduPro 13 Jun 2024 Early Stage Venture 85M United States, Washington, Seattle

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.